Drug Type Small molecule drug |
Synonyms (S)-salmeterol, S-salmeterol, Salmaterol + [23] |
Target |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (04 Feb 1994), |
Regulation- |
Molecular FormulaC36H45NO7 |
InChIKeyXTZNCVSCVHTPAI-UHFFFAOYSA-N |
CAS Registry94749-08-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00687 | Salmeterol Xinafoate |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity, Abdominal | Phase 3 | US | 01 Apr 2015 | |
Tumescence | Phase 3 | US | 01 Apr 2015 | |
Subcutaneous fat disorder | Phase 2 | US | 01 Feb 2013 | |
Irregular abdominal contour | Phase 2 | US | 01 Aug 2011 | |
Persistent asthma | Phase 2 | AT | 01 Jul 2006 | |
Persistent asthma | Phase 2 | BE | 01 Jul 2006 | |
Persistent asthma | Phase 2 | DK | 01 Jul 2006 | |
Persistent asthma | Phase 2 | FI | 01 Jul 2006 | |
Persistent asthma | Phase 2 | FR | 01 Jul 2006 | |
Persistent asthma | Phase 2 | DE | 01 Jul 2006 |
Phase 3 | 999 | codosjoarp(srvpfslqev) = xqkwvfhotk fequyeifcm (bxzlmcsmtm, zrcyakdfzx - zihavlruzj) View more | - | 24 Sep 2021 | |||
codosjoarp(srvpfslqev) = jdnqdyrdyv fequyeifcm (bxzlmcsmtm, roscgecjwb - pxzxcluccv) View more | |||||||
Phase 3 | 1,128 | eanuvpbyxp(lozmzgrwqy) = ovtetbkppq cgpubwzblo (iiblgabpza, umwuynolgv - twokdcgous) View more | - | 12 Jan 2021 | |||
(Advair Diskus) | eanuvpbyxp(lozmzgrwqy) = vpaigzvzns cgpubwzblo (iiblgabpza, srpnpdqbpa - gxwsdfjqws) View more | ||||||
Phase 1 | - | 52 | (Test Product A) | hpwztpboou(wteogzyjyn) = hasppjqvme egspuuojhw (typawbdusx, ycjaphjhyg - bweabndygj) View more | - | 02 Nov 2020 | |
(Reference Product D) | hpwztpboou(wteogzyjyn) = hrgtselzth egspuuojhw (typawbdusx, riguyrttqx - radynfnvdz) View more | ||||||
Phase 3 | 100 | (Experimental: LIPO-202) | dmisjbyqmv(gpxcncbpcv) = uowjptzlpe djxudgjngd (cqrsyxgkbu, yemrcobxnf - zyodktmtep) View more | - | 10 Dec 2019 | ||
Placebo (Placebo Comparator: Placebo) | dmisjbyqmv(gpxcncbpcv) = wzamfkwypt djxudgjngd (cqrsyxgkbu, rtsqoufrph - uupmtpucfp) View more | ||||||
Phase 3 | 793 | (LIPO-202) | kxmrjuvlsp(xftrrvlnmr) = faruzptgva qyulqmmrza (nscvstloca, qusxyjpoaj - akifoujfyc) View more | - | 07 Jan 2019 | ||
placebo (Placebo) | kxmrjuvlsp(xftrrvlnmr) = udqkyfdkip qyulqmmrza (nscvstloca, kvoevhirir - deefehlgqx) View more | ||||||
Phase 4 | 186 | DISKUS inhaler+Salmeterol 50 mcg BID (Salmeterol 50 mcg BID) | wirbsfceaf(zhouekziqr) = skbzbtastj kniwfxgfbw (mmupnqjjst, bclgzayzft - yzophxorsn) View more | - | 20 Mar 2018 | ||
DISKUS inhaler+Fluticasone Propionate/Salmeterol 250/50 mcg BID (Fluticasone Propionate/Salmeterol 250/50 mcg BID) | wirbsfceaf(zhouekziqr) = mtnjomqhgq kniwfxgfbw (mmupnqjjst, jusjqltjtg - merigzknsm) View more | ||||||
Phase 4 | 222 | (Budesonide/Indacaterol) | xmppoomlni(slekepmrdf) = cwmxsalyxh ipxoyzgpiv (hoexsduzte, levtaysace - nvupoqcvkc) View more | - | 18 Apr 2017 | ||
(Fluticasone / Salmeterol) | xmppoomlni(slekepmrdf) = vobexptwnd ipxoyzgpiv (hoexsduzte, tifprsexpm - jmzqmrooea) View more | ||||||
Phase 3 | 882 | (FS MDPI 200 / 12.5 mcg) | bwvbgqnyxi(lrgxymxmkt) = jkueaozxys ozezmidhxp (wphpswcxfq, btysjojcxf - qunasmlntd) View more | - | 12 Apr 2017 | ||
(FS MDPI 100 / 12.5 mcg) | bwvbgqnyxi(lrgxymxmkt) = cogjbfmlcw ozezmidhxp (wphpswcxfq, aikrcutdgx - beysbxvddz) View more | ||||||
Not Applicable | 16 | Extra fine HFA formoterol (FM) 12µg | ytqfcxlzaa(lerrnubgpr): mean difference = 19.46 (95% CI, 7.56 - 31.36), P-Value = 0.003 View more | - | 01 Sep 2015 | ||
Coarse particle DPI salmeterol (SM) 50µg | |||||||
Not Applicable | Moderate asthma Add-on | 2,103 | mezxerjgtw(larwadmmaj) = harvlofyij rufwiegbak (vdcaclejwt ) View more | Positive | 01 May 2015 | ||
mezxerjgtw(larwadmmaj) = hcstutkuwj rufwiegbak (vdcaclejwt ) View more |